Petros Pharmaceuticals, Inc.
1185 Avenue of the Americas, 3rd Floor
New York, New York 10036
February 3, 2021
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Attention: | Mr. Courtney Lindsay |
Re: | Petros Pharmaceuticals, Inc. |
Registration Statement on Form S-3
Filed January 29, 2021
File No. 333-252573
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Petros Pharmaceuticals, Inc. (the “Company”) hereby requests acceleration of the effective date of the above referenced registration statement so that such registration statement may become effective at 4:15 p.m. (Washington, D.C. time) on February 4, 2021, or as soon as practicable thereafter.
If the Securities and Exchange Commission has any questions concerning this request or requires any additional information, please contact Sean M. Donahue of Morgan, Lewis & Bockius LLP at (202) 739-5658. The Company respectfully requests that it be notified of the effectiveness of the registration statement by a telephone call to Mr. Donahue.
PETROS PHARMACEUTICALS, INC.
By: | /s/ FADY BOCTOR | |
Name: | Fady Boctor | |
Title: | President and Chief Commercial Officer (Principal Executive Officer) |
cc: | Sean M. Donahue, Morgan, Lewis & Bockius LLP |